Itron, Inc. ITRI
98.22 USD -1.55 (-1.55%)
At closeNov 3, 2026, 4:01 PM EST
98.23 +0.01 +0.01%
After hours · Nov 3, 4:01 PM ET
96.63 Day range 100.00
77.77 52-week range 108.20
- YTD
- +5.77%
- 1 year
- -8.04%
Analyst view
Consensus: buy
Buy
Price target (mean) 128.56 +30.9% upside
Now 98.22
- Target (low)
- 105.00
- Target (mean)
- 128.56
- Target (high)
- 150.00
Ratings (0m) 11 9 buy · 2 hold · 0 sell
- Strong buy3
- Buy6
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.75 | 1.73 – 1.82 | 2.46 | -28.7% | 628.16M | +9.9% | 7 |
| Next quarter | 1.62 | 1.53 – 1.71 | 1.49 | +8.6% | 622.06M | +6.0% | 5 |
| Current year | 6.77 | 6.75 – 6.85 | 7.13 | -5.0% | 2.38B | +0.4% | 8 |
| Next year | 6.93 | 6.50 – 7.17 | 6.77 | +2.2% | 2.52B | +6.1% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 28, 2026 | BNP Paribas | Maintained | Outperform | Outperform |
| Oct 27, 2026 | Needham | Maintained | Buy | Buy |
| Jul 29, 2026 | Needham | Maintained | Buy | Buy |
| May 20, 2026 | Stephens & Co. | Reiterated | Overweight | Overweight |
| Apr 29, 2026 | TD Cowen | Maintained | Buy | Buy |
| Apr 16, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 16, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 6, 2026 | Needham | Initiated | — | Buy |
| Feb 18, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 18, 2026 | Baird | Upgrade | Neutral | Outperform |
| Feb 17, 2026 | Guggenheim | Downgrade | Buy | Neutral |
| Feb 13, 2026 | Guggenheim | Downgrade | Buy | Neutral |
| Jan 27, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Jan 5, 2026 | Johnson Rice | Upgrade | Accumulate | Buy |
| Nov 4, 2025 | Argus Research | Downgrade | Buy | Hold |
| Oct 31, 2025 | Baird | Downgrade | Outperform | Neutral |
| Oct 16, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 7, 2025 | Stephens & Co. | Reiterated | Equal-Weight | Equal-Weight |
| Jul 31, 2025 | JP Morgan | Upgrade | Neutral | Overweight |
| Jul 22, 2025 | Roth Capital | Maintained | Buy | Buy |
| Jul 22, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Jul 14, 2025 | Guggenheim | Maintained | Buy | Buy |
| May 5, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Apr 17, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 27, 2025 | Guggenheim | Maintained | Buy | Buy |
| Feb 27, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Feb 26, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Feb 26, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 6, 2024 | Guggenheim | Maintained | Buy | Buy |